Cynomolgus KLRG1 Protein, His Tag (SPR verified)
分子別名（Synonym）
KLRG1
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Cynomolgus KLRG1 Protein, His Tag (KL1-C5243) is expressed from human 293 cells (HEK293). It contains AA Leu 60 - Pro 189 (Accession # A0A2K5WAP9).
Predicted N-terminus: His
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 18-21 kDa and 22-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
The co-inhibitory receptor killer-cell lectin like receptor G1 (KLRG1) is specifically expressed on NK cells and activated CD8+ T-cells and has been postulated to be a marker of senescence. KLRG1+ T cells are a major reason of chronic tissue damage in some autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. In tumors, tumor cells which express E-cadherin or N-cadherin bind to KLRG1 and inhibit the antitumor activity of T and NK cells. Thus, KLRG1 acts as an immunocheckpoint inhibitory receptor.
關(guān)鍵字： KLRG1;KLRG1蛋白;KLRG1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。